Clinical Trial

68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-27; most recent amendment 2024-11-12.
Trial Details
NCT Number NCT06438250
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Malignant Neoplasm
Enrollment 5 participants
Start Date 2024-03-01
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-14